NON-SMALL CELL LUNG CANCER METASTATIC
Clinical trials for NON-SMALL CELL LUNG CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER METASTATIC trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise against Hard-to-Treat lung cancer brain spread
Disease control CompletedThis study tested a combination of three drugs—high-dose furmonertinib, bevacizumab, and pemetrexed given into the spinal fluid—in 46 people with a specific type of lung cancer (EGFR-mutated) that had spread to the lining of the brain. The goal was to see if this treatment could …
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 06:48 UTC
-
Radiation boosts targeted drugs in advanced lung cancer trial
Disease control CompletedThis study tested adding a precise type of radiation (SBRT) to standard targeted therapy for people with stage IV non-small cell lung cancer that has specific gene changes (EGFR, ALK, or ROS1). The goal was to see if this combination could delay the cancer from spreading to new a…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 26, 2026 06:47 UTC
-
New cocktail of cancer drugs tested for safety in advanced tumors
Disease control CompletedThis early-phase study tested the safety of combining multiple cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 adults with advanced or metastatic solid tumors, including lung cancer. The goal was to find safe doses for future larger studies. The tr…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated May 26, 2026 06:47 UTC
-
Lung cancer combo shows promise in trial
Disease control CompletedThis study tested whether adding bevacizumab to osimertinib helps people with advanced non-small cell lung cancer that has a specific genetic change (EGFR and T790M mutations). 155 adults who had already tried other treatments took part. The main goal was to see if the combinatio…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated May 26, 2026 06:42 UTC
-
New drug combo shows promise in advanced lung cancer trial
Disease control CompletedThis early-phase study tested a combination of two drugs—nivolumab (a standard immunotherapy) and plinabulin (an experimental drug that targets tumor blood vessels and kills cancer cells)—in 18 adults with advanced non-small cell lung cancer that had worsened after chemotherapy. …
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1 • Sponsor: Lyudmila Bazhenova, M.D. • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
New approach uses targeted therapy to control metastatic lung cancer
Disease control CompletedThis study looked at whether a targeted treatment called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows rising levels of cancer DNA (minimal residual disease or MRD). 37 participants received LAT to all visible …
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Can lung cancer patients safely stop immunotherapy after 6 months?
Disease control CompletedThis study looked at 265 people with advanced non-small cell lung cancer whose tumors had a protein called PD-L1. After 6 months of treatment with two immunotherapy drugs (nivolumab and ipilimumab), half the patients stopped treatment and were watched, while the other half contin…
Matched conditions: NON-SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated May 20, 2026 11:54 UTC